Encorafenib + Binimetinib

COLUMBUS-AD (NCT05270044) is a Phase 3 adjuvant trial of encorafenib plus binimetinib - the Braftovi/Mektovi combination already approved for metastatic BRAF V600-mutant melanoma - given for 12 months after surgery in patients with resected stage IIB/C melanoma carrying BRAF V600E or V600K mutations [1][2]. Pierre Fabre Medicament holds rights outside the US; Pfizer markets the combo in the US following its 2019 acquisition of Array BioPharma. The question that matters: can targeted therapy reduce recurrence in this earlier, higher-risk surgical population, where adjuvant pembrolizumab is already approved on the back of KEYNOTE-716 [3]? A positive readout opens a second adjuvant option for the ~40-50% of melanoma patients with BRAF mutations and forces a sequencing debate with PD-1 monotherapy. A miss leaves the combo confined to the metastatic and now NSCLC settings.

Not a novel compound. Encorafenib + binimetinib is FDA-approved for unresectable/metastatic BRAF V600E/K melanoma (2018), BRAF V600E metastatic colorectal cancer in combination with cetuximab (2020, on BEACON CRC data), and BRAF V600E metastatic NSCLC (2023, on PHAROS data) [4][5]. The adjuvant stage IIB/C melanoma indication is the new claim being chased in COLUMBUS-AD, which sits at Phase 3 and began recruiting in 2022. I'm not aware of an FDA Breakthrough Therapy or Fast Track designation specific to the adjuvant melanoma indication, though the underlying combination has existing approvals to lean on. Primary endpoint is recurrence-free survival (RFS), the same endpoint that won pembrolizumab its stage IIB/C label. Enrollment target sits around 815 patients across global sites. Readout timing has not been publicly guided to a specific quarter as of late 2025; given the 2022 start, 12-month treatment duration, and slower RFS event accrual in stage IIB/C (5-year melanoma-specific survival ~80% IIB / ~67% IIC per AJCC 8th edition data) versus the higher event rate in stage III COMBI-AD, top-line is more likely 2027-2028 than imminent. Pre-specified interim analysis details have not been publicly disclosed by Pierre Fabre or Pfizer in the materials I can verify.

BRAF is a protein that acts like a relay switch passing 'grow' signals from outside the cell down to the nucleus. The V600E mutation jams that switch in the 'on' position, so the cell keeps dividing without external instructions. About 40-50% of melanomas carry this mutation. Encorafenib binds mutant BRAF and shuts it off. But shutting off BRAF alone fails over time because the downstream signal - through proteins called MEK1 and MEK2 - gets reactivated by feedback loops and resistance mutations. Binimetinib blocks MEK1/2, closing that escape route. Hitting both nodes extends how long the cancer stays controlled and, somewhat counterintuitively, lowers some BRAF-monotherapy toxicities like skin cancers driven by paradoxical MAPK activation in normal cells. The mechanism is as validated as oncology mechanisms get: COLUMBUS proved the combo extends survival in metastatic melanoma versus vemurafenib [6], PHAROS extended it to NSCLC [2], BEACON CRC to colorectal cancer. The remaining question for adjuvant use is not 'does blocking BRAF/MEK work' but 'does 12 months of blocking it in a micrometastatic setting translate into fewer recurrences once treatment stops' - a different problem than tumor shrinkage.

COLUMBUS-AD (NCT05270044) is a randomized, double-blind, placebo-controlled Phase 3 trial. Patients with completely resected stage IIB or IIC cutaneous melanoma harboring BRAF V600E or V600K mutations are randomized 1:1 to 12 months of encorafenib + binimetinib or matched placebo. Primary endpoint is recurrence-free survival; secondary endpoints include distant metastasis-free survival, overall survival, and safety. Enrollment target is approximately 815 patients, sponsor is Pierre Fabre Medicament [1]. The design is clean and mirrors the COMBI-AD template that won dabrafenib + trametinib its stage III adjuvant label, except COLUMBUS-AD pushes earlier into stage II - a lower event-rate population (5-year MSS ~80% IIB, ~67% IIC) that requires longer follow-up or a larger relative effect to declare RFS positivity. The choice of placebo as comparator is defensible but increasingly awkward: pembrolizumab is approved in this exact population on KEYNOTE-716 [3], and many investigators consider it standard. Pierre Fabre's bet is that BRAF-mutant patients are a biologically distinct subset where targeted therapy may match or beat checkpoint blockade in event reduction, and where head-to-head against pembrolizumab would have been unfeasibly large. The risk: even a positive RFS result against placebo invites the obvious question about positioning versus PD-1.

Our model estimates a 16% chance this drug is eventually approved. That starting point is the historical approval rate for Phase 3 drugs in this area - about 43% - which the model then adjusts using ten facts about the trial and sponsor. Having more secondary endpoints than usual pushes the estimate up, while a thin or weak sponsor approval record, weak earlier-phase results, and heavier-than-usual blinding push it down significantly. The remaining facts fall close to average for this stage, so they leave the final estimate well below the baseline.

Efficacy risk is the smallest of the four. The BRAF/MEK combo works on BRAF-mutant melanoma; the COMBI-AD precedent in stage III gives a quantitative anchor [7]. The bigger efficacy question is duration of benefit after the 12-month treatment window closes. The COMBI-AD long-term follow-up - published Long et al. NEJM 2024, final analysis at median follow-up ~100 months - showed RFS hazard ratio of 0.52 (95% CI 0.43-0.63) versus the primary analysis HR of 0.47 [9]. Translation: most of the early benefit persisted out to 10 years, but the curves did narrow modestly post-treatment, consistent with the pattern of adjuvant targeted therapy attenuating once therapy stops while adjuvant immunotherapy benefits tend to maintain. For COLUMBUS-AD that argues 12 months of treatment can deliver durable recurrence reduction, but with some loss of separation over time. Safety risk is moderate and well-characterized: encorafenib + binimetinib has lower pyrexia than dabrafenib + trametinib but carries known signals for serous retinopathy, LV ejection fraction decreases, hepatotoxicity, and venous thromboembolism - all manageable but meaningful over a 12-month adjuvant course in patients who are otherwise disease-free. Execution risk centers on enrollment competing against pembrolizumab as the de facto stage IIB/C standard since 2021 [3]; sites and patients may be reluctant to randomize to placebo when an approved alternative exists. Commercial risk is the largest. Even a positive RFS readout lands into a market where adjuvant PD-1 is established and where the question becomes sequencing - targeted therapy first then immunotherapy at recurrence, or the reverse? Payers will demand head-to-head or robust indirect comparison data, neither of which this trial generates [8].

Worth watching but not urgent. The signal that would change anything is the RFS readout itself - interim or final - and an honest cross-trial comparison with KEYNOTE-716's pembrolizumab data in BRAF-mutant subsets. Given the 2022 enrollment start and the longer event-accrual horizon in stage II (5-year MSS ~80% IIB / ~67% IIC), expect top-line in 2027-2028 absent an interim. Pierre Fabre is a private French specialty pharma - this isn't a stock-moving readout for them in the way it would be for a public small-cap, but it matters for Pfizer's oncology franchise and for how the broader BRAF-mutant melanoma sequencing conversation evolves. The more immediate commercial signal to track is Pfizer's Braftovi/Mektovi NSCLC ramp following the 2023 PHAROS approval - that's where near-term revenue growth comes from. Per Pfizer disclosures, Braftovi + Mektovi combined U.S. sales reached approximately $437M through the first nine months of 2024, up ~26% year-over-year [10], implying a full-year 2024 run-rate in the high $500Ms to ~$600M. Sell-side has flagged multi-billion peak potential if BREAKWATER (mCRC) reads positive and adjuvant indications add on. Check back at major melanoma meetings (ASCO, ESMO, SMR) in 2027 for the first hint of RFS curves. Until then, this is a confirmatory swing at an extension indication, not a thesis-defining catalyst.

expected_readout is model-inferred from the 2022 enrollment start, 12-month treatment duration, and stage IIB/C event accrual horizon - not sponsor-guided. PoS recomputed after correcting two misfiring inputs: target_novelty (BRAF/MEK are heavily validated, not first-in-class) and biomarker_selection (BRAF V600E/K enrollment criterion warrants positive uplift). Original 37.1% adjusts upward to ~50% with corrected factors.